Core Insights - Emcure Pharmaceuticals is leveraging social media influencers and celebrities to promote its semaglutide brand, Poviztra, aiming to establish a strong presence in the weight-loss market [1][2][4] - The marketing strategy for GLP-1 drugs is evolving, moving beyond traditional doctor-focused approaches to include broader consumer engagement, similar to trends seen in Western markets [2][10] Company Strategy - Emcure launched Poviztra in December 2023 in partnership with Novo Nordisk, and is implementing a campaign called "Winning Over Obesity" featuring celebrities and influencer-doctors to raise awareness about obesity [1][4] - The company is focusing on educating both consumers and healthcare professionals about the benefits and safety of semaglutide, addressing misinformation prevalent on social media [5][6] Market Position - Poviztra is positioned as a competitive offering in the Indian market, with a pricing structure starting at approximately ₹2,200 per week, or ₹8,790 per month, across various strengths [7] - As the generic market for semaglutide opens next month, Emcure is expected to maintain competitive pricing while expanding awareness and access to its product [8] Financial Performance - Emcure reported a profit after tax of ₹231 crore in Q3FY26, reflecting a 48.2% year-on-year increase, with revenue rising 20.4% to ₹2,363 crore, driven by strong domestic and international performance [13][14] - The domestic business grew by 15.4%, particularly in chronic therapy segments, while international operations saw a 24.5% growth, indicating robust demand across all markets [14]

Core Insights - The global pharmaceutical giants Eli Lilly and Novo Nordisk are in a fierce competition to capture the rapidly growing weight loss drug market in India before the influx of low-cost generics [1][2] - The Indian obesity drug market is expected to exceed $1 billion within two years, prompting aggressive strategies from both companies, including significant price reductions and celebrity endorsements [1][8] Pricing Strategies - Novo Nordisk has implemented a drastic price cut of approximately 37% for its weight loss drug Wegovy to counter Eli Lilly's first-mover advantage with Mounjaro [1][3] - Wegovy's monthly cost is now set at 10,850 INR (approximately $121.34), while Eli Lilly's Mounjaro remains priced higher at around 13,125 INR (approximately $146.79) [3] Market Dynamics - The competition is intensified by the impending patent cliff, with over 20 Indian pharmaceutical companies preparing to launch generics at an estimated 60% lower price once Novo Nordisk's key patent expires in March 2026 [2][5] - Eli Lilly's Mounjaro has quickly become the best-selling therapy by value in India, doubling its sales within months of its launch [3] Distribution and Marketing Efforts - Both companies are expanding their distribution networks to penetrate deeper into tier-2 and tier-3 cities, with Eli Lilly partnering with Cipla to launch a second brand targeting smaller towns [7] - Novo Nordisk has collaborated with Emcure Pharmaceuticals to extend its reach beyond major cities and has initiated campaigns to redefine obesity as a disease [7] Market Potential - The Indian weight loss drug market is currently valued at approximately 6.28 billion INR (around $70.23 million) and has grown fivefold since 2021 [8] - Analysts predict that the market will surpass $1 billion within two years, contributing significantly to the global obesity drug market, which is expected to reach $150 billion by the end of the decade [8]